Recor Medical Inc
$2.1M 2,012 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Avadel CNS Pharmaceuticals, LLC
Avadel CNS Pharmaceuticals, LLC reported $2,059,714.09 across General Payments, Research, and Ownership to 9,568 physicians and teaching hospitals across 9,583 transactions.
- $2.1M Top quartile payer
- All-tracks total
- 9,583 Top quartile volume
- Transactions
- 9,568 Top quartile reach
- Recipients
- +$1.2M
- General Payments vs PY2023
Avadel CNS Pharmaceuticals, LLC reported $2,059,714.09 across all CMS Open Payments tracks (General + Research + Ownership) to 9,568 physicians and teaching hospitals in Program Year 2024 - ranking #442 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,538,958.77, averaging $215.27 per recipient.
How Avadel CNS Pharmaceuticals, LLC's $2.1M all-tracks total breaks down
Avadel CNS Pharmaceuticals, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
67/100
Total payments
F
29/100
Transaction volume
B
80/100
Physician reach
B
83/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer avadel-cns-pharmaceuticals-llc Avadel CNS Pharmaceuticals, LLC
$2.1M · #442/1,925 · 0.0% industry · PY2024
- TOT $2.1M
- RANK #442
- SHARE 0.0%
- TXN 9,583
- RCP 9,568
- CAT 6
- GEN $1.5M
- ΔGEN +$1.2M
- TOP1 14.7%
- PY 2024
Volume peers
Nearest volume peer: Recor Medical Inc ($2.1M)
Avadel CNS Pharmaceuticals, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Avadel CNS Pharmaceuticals, LLC's CMS-reported General Payments increased by $1.2M (+337.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: AVADEL CNS PHARMACEUTICALS, LLCPY2024: Avadel CNS Pharmaceuticals, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $352,116.46
- PY2024
- $1,538,958.77
What the Data Shows for Avadel CNS Pharmaceuticals, LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Avadel CNS Pharmaceuticals, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
Of the 6 general-payment categories charted below, "Honoraria" is the largest at $781.7K across 298 transactions, 50.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Avadel CNS Pharmaceuticals, LLC made 6 types of general payments. "Honoraria" is the largest category at $781.7K, 50.8% of General Payments.
Avadel CNS Pharmaceuticals, LLC reports 6 general-payment categories - the top three are Honoraria (50.8%), Consulting Fee (19.1%), and Food and Beverage (15.9%). The remaining 3 categories make up 14.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Avadel CNS Pharmaceuticals, LLC divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $781.7K | 298 | 50.8% |
| Consulting Fee | $293.4K | 116 | 19.1% |
| Food and Beverage | $244.2K | 8,865 | 15.9% |
| Travel and Lodging | $140.2K | 281 | 9.1% |
| Compensation for Services Other Than Consulting | $58.7K | 1 | 3.8% |
| Education | $20.7K | 7 | 1.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $564,271.70 (36.7%) of $1,538,958.77 in this company's General Payments records across 2,982 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Avadel CNS Pharmaceuticals, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Jordan Dubow
$226,407.92 across 12 reported transactions
- 2
Steven Gradney
$103,773.38 across 91 reported transactions
- 3
Alon Avidan
$89,426.45 across 62 reported transactions
- 4
Anne Morse
$80,890.69 across 59 reported transactions
- 5
Matthew Davis
$63,773.26 across 71 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Avadel CNS Pharmaceuticals, LLC ranks #442 of 1,925 by total payments (top 23% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,339 of 1,838 by HHI (bottom 27% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Acclarent, Inc : $232.0K total payments, HHI 447
- Pinnacle Biologics, Inc : $70.6K total payments, HHI 445
- Gentleman Orthopedic Solutions : $20.0K total payments, HHI 445
- Blue Earth Diagnostics Limited : $324.1K total payments, HHI 444
- Trilliant Surgical LLC. : $844.6K total payments, HHI 443
- Innovasis Inc : $1.1M total payments, HHI 441
- Avadel CNS Pharmaceuticals, LLC (this company) : $1.5M total payments, HHI 441
- Intrinsic Therapeutics : $300.7K total payments, HHI 441
- Braeburn Inc. : $1.2M total payments, HHI 439
- Arthrex, Inc. : $104.3M total payments, HHI 439
- Uoc USA Inc : $460.8K total payments, HHI 437
- ZOLL Respicardia, Inc. : $325.9K total payments, HHI 435
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Avadel CNS Pharmaceuticals, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Avadel CNS Pharmaceuticals, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Avadel CNS Pharmaceuticals, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
TELA Bio, Inc.
$2.1M 7,569 recipients
Compare payment profiles
Musculoskeletal Transplant Foundation Inc.
$2.1M 3,503 recipients
Compare payment profiles
Miach Orthopaedics, Inc.
$2.1M 1,054 recipients
Compare payment profiles
ClearPoint Neuro, Inc.
$2.1M 467 recipients
Compare payment profiles
Omnia Medical, LLC
$2.0M 110 recipients
Compare payment profiles
Put this to use
Avadel CNS Pharmaceuticals, LLC ranks #442 of 1,925 by all-tracks total payments, led by "Honoraria".
- See where Avadel CNS Pharmaceuticals, LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just Avadel CNS Pharmaceuticals, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.